To demonstrate how IDACombo can be used to identify candidate combinations of more than two drugs, we performed an analysis aimed at identifying drugs that could be added to the combination of cisplatin + gemcitabine to increase the treatment’s efficacy in EGFR wild type lung cancer. Here, EGFR is linked to lung carcinoma.